FutureChem Co

FutureChem Co P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of FutureChem Co (220100.KQ) as of Oct 20, 2026 is -44.21. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was -95.13 — a change of -53.53% (higher).

P/FCF

-44.21

YoY

-53.53%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of FutureChem Co is 2025 -44.21 . P/FCF (Price-to-Free-Cash-Flow Ratio) of FutureChem Co was 2024 -95.13 . It decreases by -53.53% higher compared to the previous year.

The FutureChem Co P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2018
-41.47 KRW
Jan 1, 2019
-50.23 KRW
Jan 1, 2020
-84.76 KRW
Jan 1, 2021
-42.71 KRW
Jan 1, 2022
-45.70 KRW
Jan 1, 2023
-78.85 KRW
Jan 1, 2024
-95.13 KRW
Jan 1, 2025
-44.21 KRW
The FutureChem Co P/FCF history
YEARP/FCFYoY
-44.21-53.53%
-95.13+20.65%
-78.85+72.53%
-45.70+7.00%
-42.71-49.60%
-84.76+68.74%
-50.23+21.12%
-41.47-23.91%
-54.50-66.27%
-161.57-12.67%
-185.01—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

FutureChem Co Stock analysis

What does FutureChem Co do? FutureChem Co., Ltd. generates revenue through the manufacture and distribution of radiopharmaceuticals, including diagnostic agents for lung cancer, Parkinson's disease, and Alzheimer's disease. The company produces medical automation modules such as cubes, disposable cassettes, reagent kits, radio-caps, and kryptofix kits, alongside PET and SPECT precursors for radiopharmaceuticals. These products are sold to healthcare providers, diagnostic centers, and medical facilities requiring specialized radiopharmaceutical solutions. The firm also develops metal chelating agents and fluorescence probes for medical applications. The primary buyers of FutureChem's products include hospitals, clinics, and research institutions focused on cancer diagnostics and neurological conditions. Medical automation modules and disposable goods are utilized in diagnostic procedures, while PET and SPECT precursors support imaging technologies. Metal chelating agents and fluorescence probes are integrated into medical testing and imaging processes. FutureChem's revenue streams are driven by the demand for advanced diagnostic tools in oncology and neurology. The company's portfolio targets healthcare segments requiring early detection of diseases, with products designed for both diagnostic imaging and laboratory testing. Sales are concentrated in medical facilities that prioritize precision diagnostics and specialized treatment planning. FutureChem Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about FutureChem Co stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of FutureChem Co is -44.21 in 2025.

P/FCF (Price-to-Free-Cash-Flow Ratio) of FutureChem Co changed from -95.13 to -44.21, representing a -53.53% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) FutureChem Co since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s FutureChem Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — FutureChem Co

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — FutureChem Co